Humedix Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Humedix's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance Sheet
Mar 09
Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 16Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?
Jan 28Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 11
What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 22Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt Responsibly
Dec 01Revenue & Expenses Breakdown
How Humedix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 110,992 | 9,065 | 17,423 | 8,932 |
| 30 Sep 21 | 115,572 | 15,040 | 18,163 | 7,678 |
| 30 Jun 21 | 111,600 | 15,988 | 16,624 | 7,678 |
| 31 Mar 21 | 107,724 | 17,204 | 15,418 | 7,678 |
| 31 Dec 20 | 98,481 | 15,084 | 13,726 | 7,678 |
| 30 Sep 20 | 85,721 | 11,348 | 18,724 | 1,643 |
| 30 Jun 20 | 84,844 | 10,717 | 17,059 | 2,909 |
| 31 Mar 20 | 80,968 | 9,023 | 15,031 | 4,372 |
| 31 Dec 19 | 78,619 | 10,420 | 12,918 | 5,622 |
| 30 Sep 19 | 73,501 | 9,673 | 12,157 | 5,586 |
| 30 Jun 19 | 68,859 | 9,888 | 10,995 | 5,495 |
| 31 Mar 19 | 67,351 | 9,556 | 9,888 | 5,442 |
| 31 Dec 18 | 64,832 | 9,208 | 9,286 | 5,184 |
| 30 Sep 18 | 62,017 | 9,185 | 9,112 | 4,773 |
| 30 Jun 18 | 58,670 | 9,610 | 8,631 | 4,489 |
| 31 Mar 18 | 56,401 | 11,719 | 8,452 | 4,122 |
| 31 Dec 17 | 54,727 | 11,940 | 7,556 | 4,247 |
| 30 Sep 17 | 54,391 | 11,385 | 6,529 | 4,365 |
| 30 Jun 17 | 51,753 | 10,332 | 6,086 | 4,834 |
| 31 Mar 17 | 49,051 | 9,449 | 4,191 | 5,801 |
| 31 Dec 16 | 47,134 | 10,275 | 4,641 | 4,685 |
| 31 Dec 15 | 42,133 | 11,623 | 4,128 | 3,323 |
Quality Earnings: Insufficient data to determine if A200670 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A200670's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A200670's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A200670's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A200670's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A200670 has a negative Return on Equity (0%), as it is currently unprofitable.